A Phase 1b combination study of lifirafenib and mirdametinib in solid tumors
Completed Phase 1 NCT03905148
Study Description
A study evaluating the safety and pharmacokinetics of lifirafenib and mirdametinib combination in patients with advanced or difficult-to-treat solid tumors
Study Details
- Registry ID:
- NCT03905148
- Conditions:
- Solid Tumor, Adult
- Phase:
- Phase 1
- Target Enrollment:
- 91 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (6 sites)
-
MD Anderson
Houston, Texas, United States -
Linear Clinical Research
Nedlands, Western Australia, Australia -
University of California Los Angeles
Santa Monica, California, United States -
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia -
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia -
The Prince of Wales Private Hospital - Specialist Medical Randwick
Randwick, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.